Skip to main content

Table 1 Baseline demographic and patient characteristics

From: Omega-3 fatty acid exposure with a low-fat diet in patients with past hypertriglyceridemia-induced acute pancreatitis; an exploratory, randomized, open-label crossover study

Variable

N = 15

n (%)

Age, years

 Mean ± SD

49.8 ± 11.2

  < 65

14 (93.3)

  ≥ 65

1 (6.7)

 Women

5 (33.3)

Body mass index, kg/m2

 Mean ± SD

33.0 (7.4)

 18.5–24.9

2 (13.3)

 25.0–29.9

3 (20.0)

  ≥ 30.0

10 (66.7)

Ethnicity

 White

14 (93.3)

 Other

0 (0.0)

Triglycerides, mmol/L

 Mean ± SD

9.3 ± 9.4

 Median (range)

5.8 (3.1, 39.3)

Total cholesterol, mmol/L

 Mean ± SD

5.4 (1.8)

 Median (range)

5.0 (3.2, 8.4)

Lipid-lowering medication

 Fibrates

14 (93.3)

 Statins

12 (80.0)

 Cholesterol absorption inhibitors

3 (20.0)

History of diabetes

 Type 1

1 (6.7)

 Type 2

11 (73.3)

 Any

12 (80.0)

Diabetes medication

 Metformin

9 (60.0)

 Insulin

2 (13.3)

 Thiazolidinediones

2 (13.3)

 Dipeptidyl peptidase-4 inhibitor

1 (6.7)

 Alpha-glucosidase inhibitor

1 (6.7)

Fecal elastase, μg/g

n

14 (93.3)

 Median μg/g (range)

380 (18–500)

  1. Data are for the safety population, defined as all participants who took at least one dose of study drug (N = 15). SD standard deviation